Hypoxia-Induced O-GlcNAcylation of GATA3 Leads to Excessive Testosterone Production in Preeclamptic Placentas

Abstract

The maintenance of endocrine homeostasis in the placenta is crucial for ensuring successful pregnancy. An abnormally elevated production of placental testosterone (T₀) has been documented in patients with early-onset preeclamptic (E-PE). However, the underlying mechanisms remain unclear. In this study, we found that E-PE placentas exhibited significantly increased expressions of 3β-HSD1 (3β-Hydroxysteroid Dehydrogenase 1) and 17β-HSD3 (17β-Hydroxysteroid Dehydrogenase 3), the rate-limiting enzymes for T₀ synthesis. This was strongly correlated with an elevated level of O-linked N-acetylglucosaminylation (O-GlcNAcylation) of GATA3 (GATA binding protein 3). In human trophoblast cells, O-linked-N-acetylglucosamine (O-GlcNAc) modification of GATA3 on Thr³²² stabilized the protein and enhanced the transcriptional regulation of 3β-HSD1 and 17β-HSD3, thereby increasing T₀ production. Hypoxia, a well-established pathological factor in PE, significantly enhanced the O-GlcNAcylation of GATA3 in human trophoblast cells. Our findings suggest that hypoxia-induced overactive O-GlcNAcylation of GATA3 contributes to the exacerbated T₀ production in E-PE placentas. These findings provide a new perspective on the pathogenesis of E-PE from the standpoint of posttranslational regulation and may illuminate novel therapeutic strategies for adverse pregnancy outcomes such as E-PE.

Keywords

GATA3 / hypoxia / O-GlcNAcylation / preeclampsia / testosterone

References

[1] L. Ji, J. Brkic, M. Liu, G. Fu, C. Peng, and Y. L. Wang, “Placental Trophoblast Cell Differentiation: Physiological Regulation and Pathological Relevance to Preeclampsia,” Molecular Aspects of Medicine 34, no. 5 (2013): 981–1023.

[2] M. A. Costa, “The Endocrine Function of Human Placenta: An Overview,” Reproductive Biomedicine Online 32, no. 1 (2016): 14–43.

[3] F. Labrie, C. Martel, and J. Balser, “Wide Distribution of the Serum Dehydroepiandrosterone and Sex Steroid Levels in Postmenopausal Women: Role of the Ovary?,” Menopause 18, no. 1 (2011): 30–43.

[4] S. Makieva, P. T. Saunders, and J. E. Norman, “Androgens in Pregnancy: Roles in Parturition,” Human Reproduction Update 20, no. 4 (2014): 542–559.

[5] M. C. Honigberg, B. Truong, R. R. Khan, et al., “Polygenic Prediction of Preeclampsia and Gestational Hypertension,” Nature Medicine 29, no. 6 (2023): 1540–1549.

[6] L. E. Mignini, J. Villar, and K. S. Khan, “Mapping the Theories of Preeclampsia: The Need for Systematic Reviews of Mechanisms of the Disease,” American Journal of Obstetrics and Gynecology 194, no. 2 (2006): 317–321.

[7] M. Noris, N. Perico, and G. Remuzzi, “Mechanisms of Disease: Pre-Eclampsia,” Nature Clinical Practice Nephrology 1, no. 2 (2005): 98–114. quiz 120.

[8] A. M. Ashour, E. S. Lieberman, L. E. Haug, and J. T. Repke, “The Value of Elevated Second-Trimester Beta-Human Chorionic Gonadotropin in Predicting Development of Preeclampsia,” American Journal of Obstetrics and Gynecology 176, no. 2 (1997): 438–442.

[9] X. Shao, Y. Yang, Y. Liu, et al., “Orchestrated Feedback Regulation Between Melatonin and Sex Hormones Involving GPER1-PKA-CREB Signaling in the Placenta,” Journal of Pineal Research 75, no. 4 (2023): e12913.

[10] X. Shao, Y. Liu, M. Liu, et al., “Testosterone Represses Estrogen Signaling by Upregulating miR-22: A Mechanism for Imbalanced Steroid Hormone Production in Preeclampsia,” Hypertension 69, no. 4 (2017): 721–730.

[11] X. Shao, Y. Wang, Y. Liu, et al., “Association of Imbalanced Sex Hormone Production With Excessive Procoagulation Factor SerpinF2 in Preeclampsia,” Journal of Hypertension 37, no. 1 (2019): 197–205.

[12] M. H. Schoots, S. J. Gordijn, S. A. Scherjon, H. van Goor, and J. L. Hillebrands, “Oxidative Stress in Placental Pathology,” Placenta 69 (2018): 153–161.

[13] B. Hart, E. Morgan, and E. U. Alejandro, “Nutrient Sensor Signaling Pathways and Cellular Stress in Fetal Growth Restriction,” Journal of Molecular Endocrinology 62, no. 2 (2019): R155–R165.

[14] X. Rao, X. Duan, W. Mao, et al., “O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth,” Nature Communications 6 (2015): 8468.

[15] G. W. Hart, M. P. Housley, and C. Slawson, “Cycling of O-Linked Beta-N-acetylglucosamine on Nucleocytoplasmic Proteins,” Nature 446, no. 7139 (2007): 1017–1022.

[16] Q. Lu, X. Zhang, T. Liang, and X. Bai, “O-GlcNAcylation: An Important Post-Translational Modification and a Potential Therapeutic Target for Cancer Therapy,” Molecular Medicine 28, no. 1 (2022): 115.

[17] H. F. Wang, Y. X. Wang, Y. P. Zhou, et al., “Protein O-GlcNAcylation in Cardiovascular Diseases,” Acta Pharmacologica Sinica 44, no. 1 (2023): 8–18.

[18] M. Pantaleon, H. Y. Tan, G. R. Kafer, and P. L. Kaye, “Toxic Effects of Hyperglycemia Are Mediated by the Hexosamine Signaling Pathway and o-Linked Glycosylation in Early Mouse Embryos,” Biology of Reproduction 82, no. 4 (2010): 751–758.

[19] H. M. Brown, E. S. Green, T. C. Y. Tan, et al., “Periconception Onset Diabetes Is Associated With Embryopathy and Fetal Growth Retardation, Reproductive Tract Hyperglycosylation and Impaired Immune Adaptation to Pregnancy,” Scientific Reports 8, no. 1 (2018): 2114.

[20] C. L. Howerton, C. P. Morgan, D. B. Fischer, and T. L. Bale, “O-GlcNAc Transferase (OGT) as a Placental Biomarker of Maternal Stress and Reprogramming of CNS Gene Transcription in Development,” PNAS 110, no. 13 (2013): 5169–5174.

[21] C. L. Howerton and T. L. Bale, “Targeted Placental Deletion of OGT Recapitulates the Prenatal Stress Phenotype Including Hypothalamic Mitochondrial Dysfunction,” PNAS 111, no. 26 (2014): 9639–9644.

[22] J. Liu, X. Shao, W. Qin, et al., “Quantitative Chemoproteomics Reveals O-GlcNAcylation of Cystathionine Gamma-lyase (CSE) Represses Trophoblast Syncytialization,” Cell Chemical Biology 28, no. 6 (2021): 788–801.e5.

[23] J. Saben, Y. Zhong, S. McKelvey, et al., “A Comprehensive Analysis of the Human Placenta Transcriptome,” Placenta 35, no. 2 (2014): 125–131.

[24] C. Xu, W. Zhao, L. Peng, et al., “PRDM14 Extinction Enables the Initiation of Trophoblast Stem Cell Formation,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 208.

[25] P. Home, R. P. Kumar, A. Ganguly, et al., “Genetic Redundancy of GATA Factors in the Extraembryonic Trophoblast Lineage Ensures the Progression of Preimplantation and Postimplantation Mammalian Development,” Development (Cambridge, England) 144, no. 5 (2017): 876–888.

[26] T. C. Lai, H. F. Li, Y. S. Li, P. Y. Hung, M. K. Shyu, and M. C. Hu, “Proximal GATA-Binding Sites Are Essential for Human HSD3B1 Gene Transcription in the Placenta,” Scientific Reports 7, no. 1 (2017): 4271.

[27] A. Ralston, B. J. Cox, N. Nishioka, et al., “Gata3 Regulates Trophoblast Development Downstream of Tead4 and in Parallel to Cdx2,” Development (Cambridge, England) 137, no. 3 (2010): 395–403.

[28] J. C. H Tsang, J. S. L. Vong, L. Ji, et al., “Integrative Single-Cell and Cell-Free Plasma RNA Transcriptomics Elucidates Placental Cellular Dynamics,” PNAS 114, no. 37 (2017): E7786–E7795.

[29] W. Qin, P. Lv, X. Fan, et al., “Quantitative Time-Resolved Chemoproteomics Reveals That Stable O-GlcNAc Regulates Box C/D snoRNP Biogenesis,” PNAS 114, no. 33 (2017): E6749–E6758.

[30] W. Jia, L. Ma, X. Yu, et al., “Human CD56(+)CD39(+) dNK Cells Support Fetal Survival Through Controlling Trophoblastic Cell Fate: Immune Mechanisms of Recurrent Early Pregnancy Loss,” National Science Review 11, no. 6 (2024): nwae142.

[31] O. Genbacev, R. Joslin, C. H. Damsky, B. M. Polliotti, and S. J. Fisher, “Hypoxia Alters Early Gestation Human Cytotrophoblast Differentiation/Invasion in Vitro and Models the Placental Defects That Occur in Preeclampsia,” Journal of Clinical Investigation 97, no. 2 (1996): 540–550.

[32] M. Horii, R. Morey, T. Bui, et al., “Modeling Preeclampsia Using Human Induced Pluripotent Stem Cells,” Scientific Reports 11, no. 1 (2021): 5877.

[33] N. Noyola-Martinez, A. Halhali, and D. Barrera, “Steroid Hormones and Pregnancy,” Gynecological Endocrinology 35, no. 5 (2019): 376–384.

[34] G. J. Burton, E. Jauniaux, and A. L. Watson, “Maternal Arterial Connections to the Placental Intervillous Space During the First Trimester of Human Pregnancy: The Boyd Collection Revisited,” American Journal of Obstetrics and Gynecology 181, no. 3 (1999): 718–724.

[35] M. Knofler, S. Haider, L. Saleh, J. Pollheimer, T. Gamage, and J. James, “Human Placenta and Trophoblast Development: Key Molecular Mechanisms and Model Systems,” Cellular and Molecular Life Sciences 76, no. 18 (2019): 3479–3496.

[36] M. Tremblay, O. Sanchez-Ferras, and M. Bouchard, “GATA Transcription Factors in Development and Disease,” Development (Cambridge, England) 145, no. 20 (2018): dev164384.

[37] G. T. Ma, M. E. Roth, J. C. Groskopf, et al., “GATA-2 and GATA-3 Regulate Trophoblast-Specific Gene Expression in Vivo,” Development (Cambridge, England) 124, no. 4 (1997): 907–914.

[38] Y. K. Ng, K. M. George, J. D. Engel, and D. I. Linzer, “GATA Factor Activity Is Required for the Trophoblast-Specific Transcriptional Regulation of the Mouse Placental Lactogen I Gene,” Development (Cambridge, England) 120, no. 11 (1994): 3257–3266.

[39] Y. H. Chiu and H. Chen, “GATA3 Inhibits GCM1 Activity and Trophoblast Cell Invasion,” Scientific Reports 6 (2016): 21630.

[40] X. Yang and K. Qian, “Protein O-GlcNAcylation: Emerging Mechanisms and Functions,” Nature Reviews Molecular Cell Biology 18, no. 7 (2017): 452–465.

[41] T. Nakajima, K. Kitagawa, T. Ohhata, et al., “Regulation of GATA-binding Protein 2 Levels via Ubiquitin-Dependent Degradation by Fbw7: Involvement of Cyclin B-Cyclin-Dependent Kinase 1-Mediated Phosphorylation of THR176 in GATA-Binding Protein 2,” Journal of Biological Chemistry 290, no. 16 (2015): 10368–10381.

[42] I. Knerr, S. W. Schubert, C. Wich, et al., “Stimulation of GCMa and Syncytin via cAMP Mediated PKA Signaling in Human Trophoblastic Cells Under Normoxic and Hypoxic Conditions,” Febs Letters 579, no. 18 (2005): 3991–3998.

[43] J. Zhou, Q. K. Huynh, R. T. Hoffman, et al., “Regulation of Glutamine:Fructose-6-Phosphate Amidotransferase by cAMP-Dependent Protein Kinase,” Diabetes 47, no. 12 (1998): 1836–1840.

[44] J. A. Groves, A. O. Maduka, R. N. O’Meally, R. N. Cole, and N. E. Zachara, “Fatty Acid Synthase Inhibits the O-GlcNAcase During Oxidative Stress,” Journal of Biological Chemistry 292, no. 16 (2017): 6493–6511.

[45] H. Wang, J. W. Vant, A. Zhang, et al., “Organization of a Functional Glycolytic Metabolon on Mitochondria for Metabolic Efficiency,” Nature Metabolism 6, no. 9 (2024): 1712–1735.

[46] B. P. Luscher, C. Marini, M. S Joerger-Messerli, et al., “Placental Glucose Transporter (GLUT)-1 Is Down-Regulated in Preeclampsia,” Placenta 55 (2017): 94–99.

[47] I. Aye, C. E. Aiken, D. S Charnock-Jones, and G. C. S. Smith, “Placental Energy Metabolism in Health and Disease—Significance of Development and Implications for Preeclampsia,” American Journal of Obstetrics and Gynecology 226, no. 2S (2022): S928–S944.

[48] R. Gou and X. Zhang, “Glycolysis: A Fork in the Path of Normal and Pathological Pregnancy,” Faseb Journal 37, no. 12 (2023): e23263.

[49] H. Hosier, H. S. Lipkind, H. Rasheed, A. T. DeWan, and T. Rogne, “Dyslipidemia and Risk of Preeclampsia: A Multiancestry Mendelian Randomization Study,” Hypertension 80, no. 5 (2023): 1067–1076.

[50] Y. Yang, Y. Wang, Y. Lv, and H. Ding, “Dissecting the Roles of Lipids in Preeclampsia,” Metabolites 12, no. 7 (2022): 590.

[51] J. Mulder, D. M. Kusters, J. E. Roeters van Lennep, and B. A. Hutten, “Lipid Metabolism During Pregnancy: Consequences for Mother and Child,” Current Opinion in Lipidology 35, no. 3 (2024): 133–140.

[52] C. R. Mendelson and A. Kamat, “Mechanisms in the Regulation of Aromatase in Developing Ovary and Placenta,” Journal of Steroid Biochemistry and Molecular Biology 106, no. 1-5 (2007): 62–70.

[53] M. Hemberger, C. W. Hanna, and W. Dean, “Mechanisms of Early Placental Development in Mouse and Humans,” Nature Reviews Genetics 21, no. 1 (2020): 27–43.

[54] B. Gandevia and A. Tovell, “Declaration of Helsinki,” Medical Journal of Australia 2 (1964): 320–321.

[55] W. R. Cohen and E. A. Friedman, “Misguided Guidelines for Managing Labor,” American Journal of Obstetrics and Gynecology 212, no. 6 (2015): 753. e1–e3.

[56] B. W. J Mol, C. T. Roberts, S. Thangaratinam, L. A. Magee, C. J. M. de Groot, and G. J. Hofmeyr, “Pre-eclampsia,” Lancet 387, no. 10022 (2016): 999–1011.

[57] G. X. Zheng, J. M. Terry, P. Belgrader, et al., “Massively Parallel Digital Transcriptional Profiling of Single Cells,” Nature Communications 8 (2017): 14049.

[58] R. Satija, J. A. Farrell, D. Gennert, A. F. Schier, and A. Regev, “Spatial Reconstruction of Single-Cell Gene Expression Data,” Nature Biotechnology 33, no. 5 (2015): 495–502.

[59] A. Bagati, A. Bianchi-Smiraglia, S. Moparthy, et al., “FOXQ1 Controls the Induced Differentiation of Melanocytic Cells,” Cell Death and Differentiation 25, no. 6 (2018): 1040–1049.

[60] W. Liu, L. Zhou, C. Zhou, et al., “GDF11 Decreases Bone Mass by Stimulating Osteoclastogenesis and Inhibiting Osteoblast Differentiation,” Nature Communications 7 (2016): 12794.

[61] E. G. Ponimaskin, J. Profirovic, R. Vaiskunaite, D. W. Richter, and T. A. Voyno-Yasenetskaya, “5-Hydroxytryptamine 4(a) Receptor Is Coupled to the Galpha Subunit of Heterotrimeric G13 Protein,” Journal of Biological Chemistry 277, no. 23 (2002): 20812–20819.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.